{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:27:12Z","timestamp":1793406432724,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40121-022-00687-9","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T11:02:54Z","timestamp":1662030174000},"page":"1965-1980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of Ceftolozane\u2013Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections"],"prefix":"10.1007","volume":"11","author":[{"given":"Dana J.","family":"Holger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Rebold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alosaimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Morrisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalhamid","family":"Lagnf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Christine","family":"Belza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlan J. Kunz","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"El Ghali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Veve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-043X","authenticated-orcid":false,"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"issue":"10325","key":"687_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJ Murray","year":"2022","unstructured":"Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"key":"687_CR2","unstructured":"O\u2019Neill J. Tackling drug-resistant infections globally: final report and recommendations. Government of the United Kingdom; 2016. https:\/\/apo.org.au\/node\/63983. Accessed  15 Feb 2022."},{"issue":"3","key":"687_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"687_CR4","doi-asserted-by":"crossref","unstructured":"Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4). https:\/\/cmr-asm-org.proxy.lib.wayne.edu\/content\/32\/4\/e00031-19. Accessed  16 Jul 2020.","DOI":"10.1128\/CMR.00031-19"},{"issue":"12","key":"687_CR5","first-page":"825","volume":"39","author":"M Sorbera","year":"2014","unstructured":"Sorbera M, Chung E, Ho CW, Marzella N. Ceftolozane\/tazobactam: a new option in the treatment of complicated gram-negative infections. Pharm Ther. 2014;39(12):825\u201332.","journal-title":"Pharm Ther"},{"key":"687_CR6","unstructured":"FDA. FDA approves antibiotic to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. FDA; 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-antibiotic-treat-hospital-acquired-bacterial-pneumonia-and-ventilator-associated. Accessed  15 Feb 2022."},{"key":"687_CR7","unstructured":"FDA. FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia. FDA; 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia. Accessed  15 Feb 2022."},{"issue":"12","key":"687_CR8","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, Nov\u00e1\u010dek M, Kivistik \u00dc, et al. Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299\u2013311.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"687_CR9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/cid\/ciz816","volume":"71","author":"JM Pogue","year":"2020","unstructured":"Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020;71(2):304\u201310.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"687_CR10","doi-asserted-by":"publisher","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","volume":"5","author":"JC Gallagher","year":"2018","unstructured":"Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane\u2013tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis. 2018;5(11):ofy280.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"687_CR11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1177\/0091270003257225","volume":"43","author":"JL Kuti","year":"2003","unstructured":"Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003;43(10):1116\u201323.","journal-title":"J Clin Pharmacol"},{"key":"687_CR12","doi-asserted-by":"crossref","unstructured":"Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother. 2012. https:\/\/journals.asm.org\/doi\/abs\/10.1128\/AAC.06389-11.  Accessed  15 Feb 2022.","DOI":"10.1128\/AAC.06389-11"},{"issue":"7","key":"687_CR13","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1128\/AAC.02365-12","volume":"57","author":"KA Bauer","year":"2013","unstructured":"Bauer KA, West JE, O\u2019Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2013;57(7):2907\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"687_CR14","doi-asserted-by":"crossref","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum \u03b2-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169\u2013e183.","DOI":"10.1093\/cid\/ciaa1478"},{"issue":"3","key":"687_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/CMR.05041-11","volume":"25","author":"PD Tamma","year":"2012","unstructured":"Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450\u201370.","journal-title":"Clin Microbiol Rev"},{"key":"687_CR16","unstructured":"Centers for Disease Prevention and Control. CDC\/NHSN surveillance definitions for specific types of infections. National Healthcare Safety Network. 2022;17:1\u201330."},{"issue":"8","key":"687_CR17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1086\/671274","volume":"34","author":"M Karvouniaris","year":"2013","unstructured":"Karvouniaris M, Makris D, Manoulakas E, et al. Ventilator-associated tracheobronchitis increases the length of intensive care unit stay. Infect Control Hosp Epidemiol. 2013;34(8):800\u20138.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"11","key":"687_CR18","first-page":"1602","volume":"12","author":"S Finch","year":"2015","unstructured":"Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602\u201311.","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"687_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"687_CR20","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 30th informational supplement. CLSI document MS100. Wayne, PA: Clinical and Laboratory Standards Institute. 2020."},{"issue":"2","key":"687_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"687_CR22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services. Accessed on February 28, 2022. 2017;147."},{"issue":"3","key":"687_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotscahfer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49(3):325\u20137.","journal-title":"Clin Infect Dis"},{"key":"687_CR24","doi-asserted-by":"crossref","unstructured":"Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane\u2013tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2017 May 8. https:\/\/journals.asm.org\/doi\/abs\/10.1128\/AAC.00465-17.  Accessed 7 Feb 2022.","DOI":"10.1128\/AAC.00465-17"},{"issue":"1","key":"687_CR25","first-page":"68","volume":"32","author":"AI L\u00f3pez-Calleja","year":"2019","unstructured":"L\u00f3pez-Calleja AI, Morales EM, Medina RN, et al. Antimicrobial activity of ceftolozane\u2013tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital. Rev Esp Quimioter. 2019;32(1):68\u201372.","journal-title":"Rev Esp Quimioter"},{"issue":"1","key":"687_CR26","first-page":"e01970","volume":"62","author":"YM Wi","year":"2017","unstructured":"Wi YM, Greenwood-Quaintance KE, Schuetz AN, et al. Activity of ceftolozane\u2013tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob Agents Chemother. 2017;62(1):e01970\u2013e2017.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"687_CR27","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciaa003","volume":"71","author":"A Vena","year":"2020","unstructured":"Vena A, Giacobbe DR, Mussini C, Cattelan A, Bassetti M, Ceftabuse Study Group. Clinical efficacy of ceftolozane\u2013tazobactam versus other active agents for the treatment of bacteremia and nosocomial pneumonia due to drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020;71(7):1799\u2013801.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"687_CR28","doi-asserted-by":"publisher","first-page":"ofz408","DOI":"10.1093\/ofid\/ofz408","volume":"6","author":"T Madaline","year":"2019","unstructured":"Madaline T, Wadskier Montagne F, et al. Early infectious disease consultation is associated with lower mortality in patients with severe sepsis or septic shock who complete the 3-hour sepsis treatment bundle. Open Forum Infect Dis. 2019;6(10):ofz408.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"687_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1186\/s12879-021-06372-5","volume":"21","author":"F Chiong","year":"2021","unstructured":"Chiong F, Wasef MS, Liew KC, et al. The impact of infectious diseases consultation on the management and outcomes of Pseudomonas aeruginosa bacteraemia in adults: a retrospective cohort study. BMC Infect Dis. 2021;21(1):671.","journal-title":"BMC Infect Dis"},{"key":"687_CR30","doi-asserted-by":"crossref","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with ceftazidime\u2013avibactam for multidrug-resistant gram-negative bacterial infections. Open Forum Infect Dis. 2019;6(12). https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6934163\/.  Accessed 28 Sep 2020.","DOI":"10.1093\/ofid\/ofz522"},{"issue":"4","key":"687_CR31","doi-asserted-by":"publisher","first-page":"e02291","DOI":"10.1128\/AAC.02291-19","volume":"64","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with ceftolozane\u2013tazobactam for multidrug-resistant gram-negative bacterial infections. Antimicrob Agents Chemother. 2020;64(4):e02291\u2013319.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00687-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-022-00687-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00687-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T17:40:06Z","timestamp":1667065206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-022-00687-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s40121-022-00687-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"11 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}